Pharmaceutical engineering specialty construction and development plan
2024-01-31
Development status of Chinese pharmaceutical enterprises
The 14th Five-Year Plan for the development of pharmaceutical industry
The "Four Revolutions" of pharmaceuticals: The Singularity and the birth of Kings on the r
Pharmaceutical equipment industry: across the cyclical, to meet the new momentum
In 2023, China's pharmaceutical equipment industry will develop towards the goal of "autom
Safeguarding life safety, the "pain" and "medicine" of the pharmaceutical industry
The key technology of pharmaceutical process - What are the advances of crystallization te
Development and control of manufacturing process of chemical raw materials in "Pharmaceuti
Looking ahead to the "epidemic" : Five major issues that China's biopharmaceutical enterpr
Pharmaceutical preparation process, so that the pill smaller curative effect becomes bette
Research progress on key technologies of pharmaceutical intelligent manufacturing producti
Pharmaceutical equipment industry research in pharmaceutical industry: domestic substituti
In the field of pharmaceutical preparations, create a new blue ocean
A pill Made in China -- The leap from generic drugs to independent innovation
Carry forward the "craftsman spirit" to build China into a powerful pharmaceutical country
Star companies have fallen, microbial pharmaceutical in the end has no future?
Innovative medicine in China: A choice between two paths
Domestic generic drugs: "Youth is better than blue"
Green technology solves the problem of pharmaceutical environmental protection
Two directions of sustainable development of pharmaceutical industry: green production, en
Pharmaceutical companies flocked to layout, focus on what direction?
Innovative drugs accelerate internationalization, generic drugs need to break out of the e
What inspiration does the world's "largest generic drug" company bring to China?
A hundred years of magnificent history, there are other worlds to change the world
80 years of wind and rain, the inheritance and responsibility of "red medicine enterprises
Chinese biopharmaceutical investors are detailing 'new' drivers of growth
AI pharmaceuticals are maturing, and data sharing needs to be broken
The state encourages innovation, why should it vigorously develop generic drugs?